Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 6 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11542526

    Oncolytic adenoviral vector and methods of use

    Unleash Immuno Oncolytics, Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  2. US 11541177

    Injection spring for aged prefilled syringe and auto injector

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  3. US 11535870

    Adeno-associated virus vectors encoding modified G6PC and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  4. US 11534495

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  5. US 11530398

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  6. US 11529427

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  7. US 11529373

    Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage

    China Medical University · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  8. US 11517648

    Nanofiber paste for growth factor delivery and bone regeneration

    Northwestern University · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  9. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  10. US 11492388

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  11. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Catalyst Biosciences, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  12. US 11464856

    Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  13. US 11464737

    Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  14. US 11452782

    Liver-specific constructs factor VIII expression cassettes and methods of use thereof

    Sangamo Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  15. US 11446397

    Gene therapy vectors for treating heart disease

    Tenaya Therapeutics, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  16. US 11433097

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  17. US 11434268

    Vascular endothelial growth factor antagonists

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  18. US 11420936

    Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

    NIKANG THERAPEUTICS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  19. US 11413274

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Ligand Pharmaceuticals Incorporated · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  20. US 11406720

    Fibroblast growth factor receptor 2-specific peptide reagents and methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  21. US 11406690

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  22. US 11390687

    Bispecific antibodies against plasma kallikrein and Factor XII

    Takeda Pharmaceutical Company Limited · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  23. US 11376273

    Modulation of factor 11 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  24. US 11372008

    Blood factor monitoring assay and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted